Log in to your account:
Gilead Sciences (GILD) Underperforms Despite A Steady Stream Of Good News - Oppenheimer
August 15, 2019 7:03 AM
Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $85.00 price target on Gilead Sciences (NASDAQ: GILD) noting that the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
UPDATE: Gilead Sciences (GILD), Galapagos NV (GLPG) Report EMA Validates Marketing Application for Filgotinib for Treatment of Rheumatoid Arthritis
August 15, 2019 4:01 PM